| 1 |
Vaccinology at the beginning of the 21st century  |
미소장 |
| 2 |
Survey of human-use adjuvants.  |
미소장 |
| 3 |
New horizons in adjuvants for vaccine development  |
미소장 |
| 4 |
GuptaRK, SiberGR, Adjuvants for human vaccine—current status, problems and future prospects. Vaccine 1995; 13:1263–1276. |
미소장 |
| 5 |
Ott G, Barchfeld GL, Van Nest G, Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 1995; 13:1557–1562. |
미소장 |
| 6 |
Delivery of rapamycin to dendritic cells using degradable microparticles.  |
미소장 |
| 7 |
Enhanced antigen uptake by dendritic cells induced by the B pentamer of the type II heat-labile enterotoxin LT-IIa requires engagement of TLR2  |
미소장 |
| 8 |
Kato M, Nakamura Y, Suda T, Ozawa Y, Inui N, Seo N, Nagata T, Koide Y, Kalinski P, Nakamura H, Chida K, Enhanced antitumor immunity by superantigen-pulsed dendritic cells. Cancer Immunol Immunother 2011; 60:1029–1038. |
미소장 |
| 9 |
Saponin-based adjuvants create a highly effective anti-tumor vaccine when combined with in situ tumor destruction  |
미소장 |
| 10 |
Muzzarelli RAA, Boudrant J, Meyer D, Manno N, DeMarchis M, Paoletti MG, Current views on fungal chitin/chitosan, human chitinases, food preservation, glucans, pectins and inulin, A tribute to Henri Braconnot, precursor of the carbohydrate polymers science, on the chitin bicentennial. Carbohydr Polym 2012; 87:995–1012. |
미소장 |
| 11 |
Arai K, Kinumaki T, Fujita T, Toxicity of chitosan. Bull Tokai Reg Fish Res Lab 1968; 56:89–94. |
미소장 |
| 12 |
Biodegradation and distribution of water-soluble chitosan in mice  |
미소장 |
| 13 |
Illum L, Chitosan and its use as a pharmaceutical excipient. Pharmaceut Res 1998; 15:1326–1331. |
미소장 |
| 14 |
The safety of chitosan as a pharmaceutical excipient  |
미소장 |
| 15 |
Read RC, Naylor SC, Potter CW, Bond J, Jabbal-Gill I, Fisher A, Illum L, Jennings R, Effective nasal influenza vaccine delivery using chitosan. Vaccine 2005; 23:4367–4374. |
미소장 |
| 16 |
Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a.  |
미소장 |
| 17 |
Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan  |
미소장 |
| 18 |
Wedmore I, McManus JG, Pusateri AE, Holcomb JB, A special report on the chitosan based hemostatic dressing, Experience in current combat operations. J Trauma Acute Care Surg 2006; 60:655–658. |
미소장 |
| 19 |
Chitosan solution enhances the immunoadjuvant properties of GM-CSF  |
미소장 |
| 20 |
Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW:Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 2007; 25:2085–2094. |
미소장 |
| 21 |
In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines  |
미소장 |
| 22 |
Retinol-encapsulated low molecular water-soluble chitosan nanoparticles  |
미소장 |
| 23 |
Chitins and chitosans as immunoadjuvants and non-allergenic drug carriers.  |
미소장 |
| 24 |
Chitosan-based delivery systems for protein therapeutics and antigens  |
미소장 |
| 25 |
Peniche H, Peniche C, Chitosan nanoparticles, A contribution to nanomedicine. Polym Int 2011; 60:883–889. |
미소장 |
| 26 |
Kim TH, Nah JW, Cho MH, Park TG, Cho CS, Receptormediated gene delivery into antigen presenting cells using mannosylated chitosan/DNA nanoparticels. J Nanosci Nanotechnol 2006; 6:2796–2803. |
미소장 |
| 27 |
Solubility and structure of [formula omitted]  |
미소장 |
| 28 |
West MA, Wallin RP, Matthews SP, Svensson HG, Zaru R, Ljunggren HG, Prescott AR, Watts C, Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling. Science 2004; 305:1153–1157. |
미소장 |
| 29 |
Mikhalkevich N, Becknell B, Caliqiuri MA, Bates MD, Harvey R, Zheng WP, Responsiveness of naive CD4 T cells to polarizing cytokine determines the ratio of Th1 and Th2 cell differentiation. J Immunol 2006; 176:1553–1560. |
미소장 |
| 30 |
Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products.  |
미소장 |
| 31 |
Transport of Peptide: MHC Class II Complexes in Developing Dendritic Cells  |
미소장 |